Anti-tumour and radiosensitising effects of PARP inhibitor on cervical cancer xenografts

Anti-tumour and radiosensitising effects of PARP inhibitor on cervical cancer xenografts

This study evaluated the radiosensitising effect of niraparib; a poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor on HeLa cervical cancer cells in nude mice and explored its possible mechanism. Twenty-four 3–5-week-old female BALB/c nude mice, inoculated with HeLa cells into the right...

Full description

Bibliographic Details
Main Authors:	Qin Xue, Wang Enyang, Gong Tingting, Ma Xiaolin, Ma Qipeng, Gao Song
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-12-01
Series:	Journal of Obstetrics and Gynaecology
Subjects:	cervical cancer parp inhibitor radiotherapy radiotherapy sensitisation niraparib
Online Access:	http://dx.doi.org/10.1080/01443615.2023.2171783

Similar Items

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
by: Andrisha-Jade Inderjeeth, et al.
Published: (2022-11-01)

Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS
by: Jeanne M. Schilder, et al.
Published: (2023-08-01)

Use of First-Line PARP Inhibitors in Ovarian Cancer
by: Ursula Hasler-Strub
Published: (2020-11-01)

PARP inhibitor-related haemorrhages: What does the real-world study say?
by: Shiyan Wang, et al.
Published: (2023-02-01)

Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis
by: Xiu Chen, et al.
Published: (2023-01-01)

The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review
by: Chien-Hui Lau, et al.
Published: (2022-07-01)

Parp Inhibitors and Radiotherapy: A New Combination for Prostate Cancer (Systematic Review)
by: Inés Rivero Belenchón, et al.
Published: (2023-08-01)

Liposome Formulations for the Strategic Delivery of PARP1 Inhibitors: Development and Optimization
by: Carlota J. F. Conceição, et al.
Published: (2023-05-01)

Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study
by: Valentina Tuninetti, et al.
Published: (2023-02-01)

Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials
by: Gartrell C. Bowling, et al.
Published: (2023-10-01)

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
by: Yifan Jiang, et al.
Published: (2020-07-01)

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
by: Albert Jang, et al.
Published: (2020-11-01)

PARP inhibitors combined with radiotherapy: are we ready?
by: Chen Sun, et al.
Published: (2023-10-01)

BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy
by: Aashish Soni, et al.
Published: (2022-11-01)

LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring
by: Giovanni Canil, et al.
Published: (2023-05-01)

Real‐world data of poly (ADP‐ribose) polymerase inhibitor response in Japanese patients with ovarian cancer
by: Ryosuke Uekusa, et al.
Published: (2024-04-01)

The Combination of Radiation with PARP Inhibition Enhances Senescence and Sensitivity to the Senolytic, Navitoclax, in Triple Negative Breast Tumor Cells
by: Abrar Softah, et al.
Published: (2023-11-01)

Radiosensitizing Pancreatic Cancer with PARP Inhibitor and Gemcitabine: An In Vivo and a Whole-Transcriptome Analysis after Proton or Photon Irradiation
by: Waisse Waissi, et al.
Published: (2021-01-01)

Cervical cancer: a tale from HPV infection to PARP inhibitors
by: Minakshi Mann, et al.
Published: (2023-07-01)

Sensitization of Cancer Cells to Radiation and Topoisomerase I Inhibitor Camptothecin Using Inhibitors of PARP and Other Signaling Molecules
by: Yusuke Matsuno, et al.
Published: (2018-09-01)

PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
by: Amelia Barcellini, et al.
Published: (2021-10-01)

Cytosine–phosphate–guanine oligodeoxynucleotides alleviate radiation-induced kidney injury in cervical cancer by inhibiting DNA damage and oxidative stress through blockade of PARP1/XRCC1 axis
by: Deyu Zhang, et al.
Published: (2023-09-01)

Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset
by: Kenta Yamaoka, et al.
Published: (2022-08-01)

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
by: Isabella Faraoni, et al.
Published: (2018-12-01)

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme
by: Mary-Ann Xavier, et al.
Published: (2021-08-01)

Review of possible mechanisms of radiotherapy resistance in cervical cancer
by: Hanqun Zhang, et al.
Published: (2023-08-01)

IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation
by: Taigo Kato, et al.
Published: (2022-12-01)

Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player
by: Maria Manuela Rosado, et al.
Published: (2023-02-01)

DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy
by: Nghia T. Nguyen, et al.
Published: (2022-02-01)

The benefit of co-targeting PARP-1 and c-Met on the efficacy of radiotherapy in wild type BRAF melanoma
by: Malak Sabbah, et al.
Published: (2023-05-01)

Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents
by: Dong Zhou, et al.
Published: (2021-05-01)

PARP Inhibitors: Strategic Use and Optimal Management in Ovarian Cancer
by: Nicholas Hirschl, et al.
Published: (2024-02-01)

Determining the Potential of DNA Damage Response (DDR) Inhibitors in Cervical Cancer Therapy
by: Santu Saha, et al.
Published: (2022-09-01)

PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
by: Ahrum Min, et al.
Published: (2020-02-01)

First-Line PARP Inhibitors—Emerging Side Effects Require Caution: A Case of PARPi-Induced Pneumonitis
by: Alistair McLaren, et al.
Published: (2021-08-01)

Phase I feasibility study of Olaparib in combination with loco-regional radiotherapy in head and neck squamous cell carcinoma
by: Arash Navran, et al.
Published: (2024-01-01)

Radiotherapy and olaparib in combination for carcinoma of the oesophagus: A phase I study
by: Hamid Sheikh, et al.
Published: (2023-05-01)

Privileged Scaffolds for Potent and Specific Inhibitors of Mono-ADP-Ribosylating PARPs
by: Maria Giulia Nizi, et al.
Published: (2023-08-01)

Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
by: Joline S. J. Lim, et al.
Published: (2017-08-01)

PARP INHIBITORS IN OVARIAN CANCER: TOXICITY PROFILE
by: S. V. KHOKHLOVA, et al.
Published: (2017-06-01)